… is a novel inhibitor of cyclin-dependent kinase 4/6 which demonstrated promising anti-tumor
potency … Within the limitations of cross-trial comparison, the anti-tumor activity of single agent …

… inhibitors have demonstrated significant anti-tumor potential either as a monotherapy or
combined with other inhibitors … of transcriptional elongation has been evaluated using drugs that …

… Second, the anti-cell growth activity of different anti-tumor agents, such as the other CDK4/6
inhibitor and cytotoxic chemotherapeutic agents, was assessed. Third, to explore biological …

The development and approval of cyclin-dependent kinase (CDK) 4 and 6 inhibitors for
hormone receptor-positive and human epidermal growth factor receptor 2 (HER2)-negative …

… CDKi has synergistic activity when applied in conjunction with other targeted drugs, such
as BRAF and MEK inhibitors for malignant melanomas 3 . Most clinical trials have confirmed …

… , PI3K/ mTOR inhibitors, immunotherapy, molecularly targeted drugs, and other therapies
to … Taken together, CDK4/6 inhibition potentiates anti-tumor immunity and enhances the …

… agents employed to delay or circumvent resistance are cyclin dependent kinases 4/6 inhibitors
(… and exhausted anti-tumor immunity, CDK4/6i are unable to elicit anti-tumor responses. …

… the anti-tumor efficacy of the selective CDK 1,2,5,9 inhibitor … to other commonly used
anti-tumor compounds, we tested … doses of 28 different anti-cancer drugs in a 3D culture system. …

… of selective cyclin-dependent kinase 4 (CDK4)/6 inhibitors have been … combined with or
without other potentially active agents. … therapies actually promote anti-tumor immunity through a …

… Abstract: Cyclin-dependent kinases (CDKs) are a group of … of the CDK genes or CDK
inhibitor genes. Therefore, CDK … CDK inhibitors have been tested as antiviral agents and found …